Inside Ibrox on MSN

Rangers European campaign closes as focus turns to title race

Rangers European campaign ends in Porto, with attention now fully shifting to the Scottish Premiership title run-in under ...

AB Science receives notice of allowance for US patent covering masitinib in the treatment of metastatic castrate resistant prostate cancer

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR UNITED STATES PATENT COVERING MASITINIB IN THE TREATMENT OF METASTATIC CASTRATE RESISTANT PROSTATE CANCER THIS POSITIVE DECISION FROM THE USA ...

Infinity Capital Partners Appoints John Champagne as Partner and Chief Investment Officer

Infinity Capital Partners ("Infinity"), an alternative investment firm serving institutional investors, family offices, and RIAs, today announced that John Champagne has been appointed Partner and ...
Multiple Sclerosis News Today

Developer granted patent in Japan for masitinib use in progressive MS

AB Science has secured a patent in Japan, valid through February 2041, covering the use of masitinib for progressive forms of MS.
Devdiscourse

Champions League Showdown: European Giants Battle for Playoff Spots

European soccer heavyweights, including PSG, Real Madrid, Barcelona, and City, face crucial matches in the Champions League.

As Alberta's population and employment climbs, 'Alberta's Top Employers (2026)' double down on training and development

With Alberta's population continuing to set records and employment growth leading the country, the province's best employers are investing more than ever in training, skills development and career ...

Eisai submits Marketing Authorisation Variation to EMA for intravenous maintenance dosing every four weeks with Leqembi® (lecanemab)

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai announced today that they have submitted a proposed Marketing ...

Leqembi® Iqlik™ (lecanemab-irmb) supplemental Biologics License Application regarding subcutaneous starting dose granted Priority Review by the US FDA

BioArctic AB's (publ) (STO: BIOA B) partner Eisai announced today that the supplemental Biologics License Application (sBLA) for Leqembi ...
Pharmabiz

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis

AB Science receives Japanese patent for use of masitinib in progressive forms of multiple sclerosis: Paris Friday, January 23, 2026, 14:00 Hrs [IST] AB Science SA, a pharmaceutica ...

AB Science receives Japanese patent protection for the use of masitinib in progressive forms of multiple sclerosis (MS) until 2041

PRESS RELEASEAB SCIENCE RECEIVES JAPANESE PATENT PROTECTION FOR THE USE OF MASITINIB IN PROGRESSIVE FORMS OF MULTIPLE SCLEROSIS (MS) UNTIL ...
ABC News

New drug may slow progression of ALS in small group of patients: Study

The drug targets a specific mutation that applies to only 2% of ALS patients. A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS ...